Transforming Medicine: TMed Will Match People with Life-Threatening Illnesses to Best Treatments, in Real Time
I believe that the dialogue and thoughts being shared and expressed by all cancer care stakeholders is exactly what we need today. Frankly, the conversation has been underground far too long, but the headlines today have been focused solely on the drug cost. Anyone thinking that cancer care costs are going to go down, simply doesn’t understand healthcare economics, because the cost to society will continue to go up over time, with true innovation and value delivered.
- FDA Approved Gefitinib with a Companion Diagnostic Test for First-Line Treatment of Patients with Metastatic Lung Cancer and EGFR Mutations
- Sonidegib Approved for Locally Advanced Basal-Cell Carcinoma
- Brentuximab Vedotin Receives New Indication for Patients with Hodgkin Lymphoma
- Rolapitant a New Antiemetic Agent Approved for CINV Prevention
Boston, MA—Researchers have defined an 81-feature molecular signature to identify neuroendocrine prostate cancer (NEPC), an aggressive and rapidly progressing entity that is increasingly being recognized in patients with advanced disease and signals poor overall survival. The signature, derived from genomic, transcription, and methylation analysis, relies heavily on epigenetic alterations.
Boston, MA—Rociletinib, a specially engineered third-generation EGFR inhibitor, is accumulating an impressive track record in early studies of non–small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the T790M mutation, a heretofore patient population with unmet needs. T790M, the most common mutation associated with resistance to first-line EGFR-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs.
Medical and Psychosocial Impact of Oral Therapy on Patients with Metastatic Castration-Resistant Prostate Cancer
San Diego, CA—The introduction of 2 therapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)—the orally administered abiraterone acetate (Zytiga) and enzalutamide (Xtandi)—has prompted Leslie Hazel-Fernandez, PhD, Comprehensive Health Insights, Louisville, KY, and colleagues to conduct a qualitative study to evaluate the personal and other factors that influence the use of oral drugs among patients with mCRPC, as well as to gauge caregivers’ and physicians’ experiences with patients who use these oral medications. The results of this study were presented at the 2015 Academy of Managed Care Pharmacy annual meeting.
Page 1 of 2
Results 1 - 10 of 19
Results 1 - 10 of 19